Long-Term Treatment of BIIB092 (Gosuranemab) in PSP

Phase 1, open-label trial of gosuranemab in progressive supranuclear palsy (PSP) (4 arms), sponsored by Biogen. Primary endpoints: Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Deaths at 1.5 years and Percentage of Participants with Marked Abnormalities in Clinical Laboratory Tests, Vital sign Measurements, ECGs, and Physical and Neurological Examinations at 1.5 years. Started Feb 2016; status: terminated.